Related Experiment Video
Updated: Sep 26, 2025

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
Sara Arfan1, Abdelrahman Zamzam1, Muzammil H Syed1
1Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
Insights
Elevated D-dimer and prothrombin fragment (F1+2) levels predict disease progression in peripheral artery disease (PAD). These biomarkers help stratify risk for major adverse limb events (MALE) and declining ankle-brachial index (ABI).
Area of Science:
- Biochemistry
- Vascular Medicine
- Clinical Diagnostics
Background:
- Peripheral artery disease (PAD) is characterized by elevated D-dimer and prothrombin fragment 1+2 (F1+2) levels.
- These biomarkers are associated with increased thrombotic activity and vascular inflammation.
Purpose of the Study:
- To investigate the prognostic value of baseline D-dimer and F1+2 in predicting disease progression and major adverse limb events (MALE) in PAD patients.
- To assess the correlation between these biomarkers and ankle-brachial index (ABI) changes over time.
Main Methods:
- A prospective cohort study involving 206 PAD patients followed for two years.
- Baseline plasma levels of D-dimer and F1+2 were measured.
- Pearson's correlation, multivariable Cox proportional hazard analysis, and Kaplan-Meier survival analysis were employed.
Main Results:
- PAD patients exhibited significantly higher D-dimer and F1+2 levels compared to controls.
- Both D-dimer and F1+2 were negatively correlated with ABI at two years.
- Elevated D-dimer and F1+2 independently predicted PAD status, decreasing ABI, and MALE.
Conclusions:
- Combined analysis of D-dimer and F1+2 provides crucial prognostic information for PAD.
- These biomarkers aid in risk stratification for disease progression and adverse limb outcomes in PAD patients.
Abstract:
D-dimer and prothrombin fragment (F1+2) levels are elevated in patients with peripheral artery disease (PAD). We examined their prognostic potential in predicting decreasing ABI and major adverse limb events (MALE). A total of 206 patients were recruited from St. Michael’s Hospital and followed for two years. Baseline plasma concentrations of D-dimer and F1+2 were recorded. Pearson’s correlation was used to assess the correlation between the biomarkers and ABI at year 2. During follow-up, multivariable Cox proportional hazard analysis was performed to investigate their role in predicting decreasing ABI (defined as change in ABI > −0.15) and MALE (defined as the need for arterial intervention or major limb amputation). Cumulative survival was assessed using Kaplan−Meier analysis. Baseline D-dimer and F1+2 levels were elevated in PAD patients (median (IQR) 1.34 (0.80−2.20) for D-dimer and 3.60 (2.30−4.74) for F1+2; p = 0.001) compared to non-PAD controls (median (IQR) 0.69 (0.29−1.20) for D-dimer and 1.84 (1.17−3.09) for F1+2; p = 0.001). Both markers were negatively correlated with ABI at year 2 (r = −0.231 for D-dimer, r = −0.49 for F1+2; p = 0.001). Cox analysis demonstrated F1+2 and D-dimer to be independent predictors of PAD status (HR = 1.27, 95% CI = 1.15−1.54; p = 0.013 for D-dimer and HR = 1.28, 95% CI = 1.14−1.58; p = 0.019 for F1+2). Elevated baseline concentrations of D-dimer and F1+2 were associated with high incidence of decreasing ABI and 1- and 2-year event-free survival (62% and 86%, respectively). Combined analysis of D-dimer and F1+2 provides important prognostic information that facilitates risk stratification for future disease progression and MALE outcomes in patients with PAD.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

